<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pasithea Therapeutics Corp. — News on 6ix</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp</link>
<description>Latest news and press releases for Pasithea Therapeutics Corp. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 04 May 2026 11:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pasithea-therapeutics-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358efb78dffbe2df101702.webp</url>
<title>Pasithea Therapeutics Corp.</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp</link>
</image>
<item>
<title>Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-appointment-of-kartik-krishnan-md-phd-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-appointment-of-kartik-krishnan-md-phd-as-chief-medical-officer</guid>
<pubDate>Mon, 04 May 2026 11:01:00 GMT</pubDate>
<description>MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (CMO) of the Company, effective May 1, 2026. Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neur</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-grant-of-rare-pediatric-disease-designation-rpdd-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-grant-of-rare-pediatric-disease-designation-rpdd-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1</guid>
<pubDate>Mon, 20 Apr 2026 11:01:00 GMT</pubDate>
<description>Rare Pediatric Disease Designation may render Pasithea eligible to receive a Priority Review Voucher (PRV)MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to PAS-004 for treatment of Neurofibromatosis type-1 (NF1). Th</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-grant-of-fast-track-designation-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1-associated-plexiform-neurofibromas-pn-causing-significant-morbidity-1</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-grant-of-fast-track-designation-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1-associated-plexiform-neurofibromas-pn-causing-significant-morbidity-1</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to</description>
</item>
<item>
<title>Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-present-oppenheimer-36th-120100465</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-present-oppenheimer-36th-120100465</guid>
<pubDate>Tue, 17 Feb 2026 12:01:00 GMT</pubDate>
<description>– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheim</description>
</item>
<item>
<title>Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-provides-outlook-pas-120100012</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-provides-outlook-pas-120100012</guid>
<pubDate>Tue, 13 Jan 2026 12:01:00 GMT</pubDate>
<description>MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), today provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN patients. Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-closing-60-120000379</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-closing-60-120000379</guid>
<pubDate>Tue, 02 Dec 2025 12:00:00 GMT</pubDate>
<description>Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the tre</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-pricing-60-142000155</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-pricing-60-142000155</guid>
<pubDate>Fri, 28 Nov 2025 14:20:00 GMT</pubDate>
<description>Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management MIAMI, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associ</description>
</item>
<item>
<title>Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-1-million-120000595</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-1-million-120000595</guid>
<pubDate>Tue, 25 Nov 2025 12:00:00 GMT</pubDate>
<description>-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage biomarker-driven clinical trials of novel or repurposed therapeutics for ALS -- MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today an</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-completion-cohort-120000265</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-completion-cohort-120000265</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin ratio <2. Achieved exposures (AUC) of 6,690 ng·h/mL – -- Pharmacodynamic (PD) data support continuous suppression of MAPK pathway throughout the 24-hour cycle – -- Safety Review Committee recommended that trial escalate to the next dose level Cohort (Cohort 8, 45mg capsules) – MIAMI, Nov. 24, 2025 (GLOBE</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-positive-pas-173500330</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-positive-pas-173500330</guid>
<pubDate>Fri, 21 Nov 2025 17:35:00 GMT</pubDate>
<description>-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced variability -- -- Tablet steady state showing Cmax/Cmin ratio <2 -- MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macr</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-positive-phase-210100333</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-positive-phase-210100333</guid>
<pubDate>Thu, 20 Nov 2025 21:01:00 GMT</pubDate>
<description>-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable disease and remains on trial for more than 6 months -- -- Initial Disease Control Rate in efficacy evaluable patients of 71.4% with BRAF-mutated tumors: 5 of 7 patients achieved stable disease -- -- Favorable Safety Pr</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-activation-clinical-120300246</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-activation-clinical-120300246</guid>
<pubDate>Tue, 04 Nov 2025 12:03:00 GMT</pubDate>
<description>Platinum sponsorship of NF Caregivers Symposium reinforces commitment to NF1 communityMIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced activation of a new U.S. clinical trial site at the University of Alabama at Birmingham (“UAB”) for its ongoing Phase 1/1b open-label study evaluating PAS-004 in adult patien</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-activation-clinical-110300880</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-activation-clinical-110300880</guid>
<pubDate>Tue, 16 Sep 2025 11:03:00 GMT</pubDate>
<description>First patient in South Korea dosedMIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced activation of two South Korean clinical trial sites participating in its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004, in adult participants with neurofi</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-enrollment-cohort-110100187</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-enrollment-cohort-110100187</guid>
<pubDate>Mon, 08 Sep 2025 11:01:00 GMT</pubDate>
<description>-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced that the external Safety Review Committee recommended that the Company’s Phase 1/1b open label study to assess t</description>
</item>
<item>
<title>Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-updates-time-presentation-123900194</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-updates-time-presentation-123900194</guid>
<pubDate>Fri, 29 Aug 2025 12:39:00 GMT</pubDate>
<description>MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City, to Monday, September 8, at 5:00 PM Eastern Time. Pasithea CEO, Dr. Tiago Reis Marques, wil</description>
</item>
<item>
<title>Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-present-h-c-110200790</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-present-h-c-110200790</guid>
<pubDate>Thu, 28 Aug 2025 11:02:00 GMT</pubDate>
<description>MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced management will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City. Pasithea CEO, Dr. Tiago Reis Marques, will deliver a live company presentation and management will be available for one-</description>
</item>
<item>
<title>Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-completes-enrollment-initial-110100337</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-completes-enrollment-initial-110100337</guid>
<pubDate>Thu, 31 Jul 2025 11:01:00 GMT</pubDate>
<description>– Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 –MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven indications, today announced the Company has completed enrollment and initial dosing of three subj</description>
</item>
<item>
<title>Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-appoints-expert-ets2-110200392</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-appoints-expert-ets2-110200392</guid>
<pubDate>Wed, 11 Jun 2025 11:02:00 GMT</pubDate>
<description>Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as inflammatory bowel disease (IBD)MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the</description>
</item>
<item>
<title>Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-presents-updated-interim-120200039</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-presents-updated-interim-120200039</guid>
<pubDate>Mon, 02 Jun 2025 12:02:00 GMT</pubDate>
<description>-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior lines of therapy, including a prior MEK inhibitor + BRAF inhibitor combination therapy, achieves over 5 months of stable disease with tumor volume reduction of -14.9% and remains on treatment -- -- PAS-004 pharmacokinetics profile potentially support</description>
</item>
<item>
<title>Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases</title>
<link>https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-preclinical-data-110100081</link>
<guid isPermaLink="true">https://6ix.com/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-preclinical-data-110100081</guid>
<pubDate>Tue, 20 May 2025 11:01:00 GMT</pubDate>
<description>-- Demonstrates PAS-004’s potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases – -- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway – -- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven In</description>
</item>
</channel>
</rss>